Notably, the selective TRPV4 antagonist, GSK2798745, has succeeded in entering clinical trials (Phase I and Phase II) as a drug candidate for the treatment of several disorders (https://clinicaltrials.gov accessed on 22 January 2025), including HF (NCT02119260). This evidence concerns the gene TRPV4 and hydrops fetalis.